Trinity Biotech (TRIB) Non-Current Debt (2009 - 2025)

Trinity Biotech's Non-Current Debt history runs 15 years deep, the most recent figure standing at $83.6 million for Q2 2025.

• In Q2 2025, Non-Current Debt rose 27.1% year-over-year to $83.6 million; the TTM figure through Jun 2025 stood at $83.6 million (up 27.1% YoY), while the FY2024 annual figure was $72.4 million, up 80.49% from the prior year.
• Non-Current Debt came in at $83.6 million for Q2 2025 at Trinity Biotech, up from $72.4 million in the prior quarter.
• In the past five years, Non-Current Debt ranged from a high of $83.6 million in Q2 2025 to a low of $31000.0 in Q4 2021.
• A 5-year average of $51.8 million and a median of $46.8 million in 2022 frame the typical range for Non-Current Debt.
• Across the five-year window, Non-Current Debt jumped 142806.45% in 2022 and slumped 35.47% in 2023, its largest moves.
• Trinity Biotech's Non-Current Debt stood at $31000.0 in 2021, then surged by 142806.45% to $44.3 million in 2022, then fell by 9.46% to $40.1 million in 2023, then surged by 80.49% to $72.4 million in 2024, then grew by 15.54% to $83.6 million in 2025.
• According to Business Quant data, Non-Current Debt over the past three periods registered $83.6 million, $72.4 million, and $66.4 million for Q2 2025, Q4 2024, and Q3 2024 respectively.

Peer Comparison